Pharmafile Logo

Institute of Medicine

- PMLiVE

Juno cleared to restart CAR-T trial after deaths

Study attributes fatalities to pre-conditioning therapy, not the cancer immunotherapy

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

- PMLiVE

Tracking comms trends: tackling reputational issues head on

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

Novartis Gehry Building

Heart failure drug Entresto ‘could save 28,000 lives a year’

New independent report looks set to boost sales of Novartis’ drug into blockbuster territory

- PMLiVE

Merck starts pivotal trials of new antibiotic combination

Continues testing after positive phase II results for relebactam addition 

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

- PMLiVE

Circassia slumps as cat allergy vaccine fails late-stage trial

Has suspended several trials after an “unprecedented” placebo effect derailed leading drug candidate

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

- PMLiVE

GSK and J&J move closer to sirukumab filing for arthritis

On course for third quarter application in a bid to catch up with Sanofi’s sarilumab

- PMLiVE

Leveraging HCP transparency insights to drive future customer investments

EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links